OSE Immunotherapeutics
OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments
May 24, 2024Research and Development Boehringer Ingelheim, Cancer, Cardiology, OSE Immunotherapeutics, cardio-renal-metabolic diseases
OSE Immunotherapeutics and Boehringer Ingelheim have announced a major expansion of their existing partnership. The expansion includes two new projects …
OSE Immunotherapies’ UC drug gets DSMB positive recommendation
July 6, 2023Research and Development EMA, Gastrointestinal tract, OSE Immunotherapeutics, ulcerative colitis
French biotech company OSE Immunotherapeutics has announced that its Ulcerative Colitis (UC) trial’s Independent Drug Safety Monitoring Board (DSMB) has provided …
Boehringer teams up with OSE in €1.1 billion cancer drug partnership
April 5, 2018Sales and Marketing Boehringer, Cancer, OSE Immunotherapeutics, partnership, pharma
Boehringer Ingelheim and biotech firm OSE Immunotherapeutics have announced that they have entered an exclusive collaboration and license agreement to …
